Steady-State Disposition of the Nonpeptidic Protease Inhibitor Tipranavir when Coadministered with Ritonavir - Chen, Linzhi; Sabo, John P.; Philip, Elsy; Mao, Yanping; Norris, Stephen H.; MacGregor, Thomas R.; Wruck, Jan M.; Garfinkel, Sandra; Castles, Mark; Brinkman, Amy; Valdez, Hernan (Antimicrobial Agents and Chemotherapy, 2007)
Keywords: Administration, Oral; Anti-HIV Agents; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - blood; Anti-HIV Agents - metabolism; Anti-HIV Agents - pharmacokinetics; Anti-HIV Agents - urine; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Capsules; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Feces - chemistry; HIV Protease Inhibitors; HIV Protease Inhibitors - administration & dosage; HIV Protease Inhibitors - adverse effects; HIV Protease Inhibitors - blood; HIV Protease Inhibitors - metabolism; HIV Protease Inhibitors - pharmacokinetics; HIV Protease Inhibitors - urine; Humans; Male; Medical sciences; Pharmacology; Pharmacology. Drug treatments; Pyridines; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - blood; Pyridines - metabolism; Pyridines - pharmacokinetics; Pyridines - urine; Pyrones; Pyrones - administration & dosage; Pyrones - adverse effects; Pyrones - blood; Pyrones - metabolism; Pyrones - pharmacokinetics; Pyrones - urine; Ritonavir; Ritonavir - administration & dosage; Ritonavir - adverse effects; Ritonavir - blood; Ritonavir - metabolism; Ritonavir - pharmacokinetics; Ritonavir - urine; Peptidases; Antiretroviral agent; Tipranavir; Enzyme; Ritonavir; Enzyme inhibitor; Hydrolases; Antiviral; Non peptide compound; Pharmacokinetics; Protease inhibitor